The approaching expiration of Ozempic’s Brazilian patent—a diabetes drug widely used for weight loss—has triggered a dispute in Congress. Denmark’s Novo Nordisk, whose patent expires in March, is ...
You can't hold back time, but scientists believe they may finally be able to slow down ageing. In a revolutionary new field, ...
The hospitalization news comes months after Quinton Aaron flaunted his incredible weight loss transformation, sparking Ozempic allegations.
A US investment bank is already eyeing the benefits of lighter passengers for the airlines in reduced fuel costs.
Zacks Investment Research on MSN
How will Ozempic and Wegovy sales aid NVO's upcoming Q4 results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...
Anything that helps Americans lose weight, reduces treatment barriers and makes care more affordable should be welcomed. But let's not fool ourselves.
As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results